Susquehanna Fundamental Investments, LLC Leap Therapeutics, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.42 - $9.18 $35,074 - $766,630	-83,511 Reduced 82.08%	18,229 $8,000
Q1 2022 May 16, 2022	BUY	$1.6 - $3.35 $143,881 - $301,252	89,926 Added 761.18%	101,740 $178,000
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $24,573 - $43,121	11,814 New	11,814 $38,000
Q2 2021 Aug 11, 2021	SELL	$1.48 - $1.92 $105,777 - $137,224	-71,471 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.82 - $3.01 $977 - $1,616	-537 Reduced 0.75%	71,471 $136,000
Q4 2020 Feb 16, 2021	SELL	$1.49 - $2.37 $51,393 - $81,746	-34,492 Reduced 32.39%	72,008 $162,000
Q3 2020 Nov 16, 2020	BUY	$1.68 - $2.17 $160,776 - $207,669	95,700 Added 886.11%	106,500 $211,000
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $15,011 - $30,672	10,800 New	10,800 $23,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $344M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.